Thu, Oct. 1, 8:42 AM
- Teva Pharmaceutical Industries (NYSE:TEVA) acquires Mexico City-based Representaciones e Investigaciones Medicas, S.A. de C.V. (Rimsa) for $2.3B. The transaction establishes Teva as the leading pharma firm in Mexico and positions it for long-term growth in Latin America.
- Rimsa's revenues for 2014 were $227M with an annual top-line growth rate of over 10%.
- The deal, funded with cash on hand and lines of credit, should close in Q1. It is expected to be accretive to Teva's non-GAAP earnings starting Q1 2017.
- TEVA is up 2% premarket on average volume.
Fri, Sep. 25, 9:38 AM
- Teva Pharmaceutical Industries (NYSE:TEVA) acquires Cambridge, MA-based Gecko Health Innovations for an undisclosed sum. Gecko creates smart solutions that help patients with chronic diseases to better manager their condition. With an initial focus on COPD and asthma, it has designed and built hardware and software solutions to collect and present important data in a high-value-added way using behavioral tools to promote better disease management. It launched CareTRx this year, which is a cloud-based solution designed to simplify chronic respiratory disease management via connecting patients and caregivers through remote monitoring and real-time adherence tools.
- The acquisition will allow Teva to explore innovative ways to apply the CareTRx technology to its pipeline and portfolio of respiratory products with the aim of improving clinical outcomes for patients.
Mon, Aug. 3, 8:30 AM
- To further its emphasis on personalized medicine, Teva Pharmaceutical Industries (TEVA -0.1%) establishes a 51% equity stake in privately-held Cambridge, MA-based Immuneering, a genomic analysis company that employs proprietary algorithms using genetic, genomic and proteomic data to generate biological insights that enhance the clinical and commercial success of medicines.
- The firms have been working together over the past several years in characterizing non-biological complex drugs in addition to genetic biomarkers and therapy-specific gene expression signatures. Teva has the right of first refusal in projects related to Immuneering's work in central nervous system disorders.
- The specific amount of Teva's investment is not disclosed.
Mon, Jul. 27, 7:09 AM
- Mylan (NASDAQ:MYL) drops 12% premarket on increased volume in response to Teva's (NYSE:TEVA) $40.5B deal for Allergan's (NYSE:AGN) generics business, dashing investors' hopes that it would pursue its hostile bid for Mylan.
- In a statement, Mylan reaffirms its interest in Perrigo. A vote on the combination by Mylan shareholders is expected to happen in the next few weeks.
Mon, Jul. 27, 5:19 AM
- Teva Pharmaceuticals (NYSE:TEVA) has agreed to buy the generic-drug business of Allergan (NYSE:AGN) for about $40.5B in cash and stock, ending its effort to acquire rival Mylan (NASDAQ:MYL).
- Allergan will receive $33.75B in cash and shares in Teva valued at $6.75B, giving it a 10% stake in the enlarged company.
- The acquisition further extends a wave of mergers that has swept over the healthcare industry. Pharmaceutical deals so far this year have topped $180B, on pace to beat the $200B announced in 2014.
- TEVA +12.1% premarket
Mon, Jul. 27, 3:40 AM| Mon, Jul. 27, 3:40 AM | Comment!
Sun, Jul. 26, 6:37 AM
- Teva Pharmaceuticals (NYSE:TEVA) is in advanced talks to buy Allergan's (NYSE:AGN) generic drug business following an unsuccessful effort to acquire Mylan (NASDAQ:MYL), WSJ reports.
- A deal for the business, valued at about $45B, could be announced as early as Monday and would extend the recent wave of mergers that has swept over the healthcare industry.
- Previously: Bloomberg: Allergan thinking of selling/spinning off generics business (Jul. 24 2015)
Thu, Jul. 23, 1:06 PM
- An independent Dutch foundation, Stichting Preferred Shares Mylan, exercises its call option allowing it to purchase 50% of Mylan's (MYL -1.4%) shares, giving it temporary control of half the company. The call option (i.e., poison pill), a common feature in Netherlands-based foundations, is a mechanism by which these groups can block unwelcome bids like the one from Teva Pharmaceutical Industries (TEVA). According to Stichting, it is acting to "safeguard Mylan's stakeholder interests." Mylan rejected Teva's $40B offer in April.
- In a statement, Teva said it has the power to challenge to foundation's action in court and that it would "take the necessary actions at the appropriate time."
Mon, Jul. 6, 12:25 PM
Fri, Jun. 19, 10:42 AM
- Teva Pharmaceutical Industries (TEVA +0.2%) completes its accumulation of a 4.61% stake on Mylan N.V. (MYL -0.3%) which enables Teva to commence proceedings before the Dutch Enterprise Chamber, should it become necessary.
- In addition, Teva commits to limit its stake to less than 5% if Mylan holds its shareholders meeting no later than August 31.
Thu, Jun. 11, 6:47 AM
- Teva Pharmaceutical (NYSE:TEVA) has now raised its stake in Mylan (NASDAQ:MYL) to 3%, as part of its effort to acquire its rival, Globes reports.
- Yesterday, Teva bought about 1.3M shares in Mylan for close to $100M and has now paid about $1.1B for a total of 14.9M shares.
- Previously: Reuters: Teva set to raise stake in Mylan (Jun. 03 2015)
Wed, Jun. 10, 2:20 AM
- A Pennsylvania judge has recommended Kirkland & Ellis be prevented from advising Teva Pharmaceutical (NYSE:TEVA) on its attempted takeover of Mylan (NASDAQ:MYL) after the law firm represented Mylan on other matters.
- The report is likely to shake up a bitter, three-way takeover battle. Mylan has rejected Teva's bid in unusually harsh terms and is instead plowing ahead with its own, twice-rejected offer for Perrigo (NYSE:PRGO).
Tue, Jun. 9, 11:54 AM
- Proactiveinvestors' Philip Waller says if AstraZeneca (AZN -1.1%) doesn't get serious it will miss out on an attractive acquisition candidate that would boost its pipeline, something it needs to do if it hopes to achieve its previously announced goal of $45B in revenues by 2023.
- The target is San Diego, CA-based Receptos (RCPT +0.3%), a clinical stage biopharmaceutical firm with two promising drugs in development: RPC1063 for relapsing multiple sclerosis and inflammatory bowel disorders and RPC4046 for eosinophilic esophagitis.
- The company has already approached Receptos about a $200 per share bid but it was rejected as were higher bids of ~$280 per share from (TEVA -0.3%) and Gilead Sciences (GILD +1.2%). Receptos is reportedly holding out for $350 per share which would value it at ~$11B or a 124% premium to its current valuation.
- An AZN spokesperson says, "We wouldn't comment on market rumour or speculation."
Mon, Jun. 8, 3:36 PM
- In yet another letter, Mylan (MYL -0.5%) Executive Chairman Robert Coury wants (TEVA -0.9%) to answer two simple questions: Are you going to make a formal offer for us? If so, are you willing to do whatever the U.S. Federal Trade Commission stipulates to make the deal happen?
- A response letter from Teva will, no doubt, be sent shortly.
Mon, Jun. 8, 1:15 PM
- In a letter to Mylan (MYL -0.6%) Executive Chairman Robert Coury, Teva Pharmaceutical Industries' (TEVA +0.2%) President & CEO Erez Vigodman responds to Mylan's rather negative perceptions about the latter's intent regarding a takeover bid. Teva appears committed to getting a deal done and asserts that Mylan is the one who is holding things up.
- Mylan is on the prowl for generic drug firm Perrigo (PRGO -0.9%), who keeps rejecting its offers, the latest at $34B. Teva made a $40B bid for Mylan in April that Mylan rejected.
Tue, Jun. 2, 3:29 AM
- Mylan (NASDAQ:MYL) has accused Teva Pharmaceutical (NYSE:TEVA), which made a $40B unsolicited offer for the company in April, of violating U.S. anti-trust rules through its recent purchase of a 1.35% stake in the company.
- Mylan, which is attempting to buy Perrigo (NYSE:PRGO) for $34B, also told Teva to "stop playing games" and either turn its $40B approach into a formal bid or walk away.
- A takeover by Teva would torpedo any Mylan deal with Perrigo.
TEVA vs. ETF Alternatives
Other News & PR